Axcrona, Karol2; Aaltomaa, Sirpa2; da Silva, Carlos Martins2; Ozen, Haluk2; Damber, Jan-Erik2; Tankó, László B2; Colli, Enrico2; Klarskov, Ole Peter1
1 Urology, Herlev and Gentofte Hospital, The Capital Region of Denmark2 unknown
degarelix vs goserelin plus bicalutamide
Study Type--Therapy (RCT) Level of Evidence 1b. What's known on the subject? and What does the study add? Androgen deprivation therapy (ADT) is commonly used as a primary treatment for patients with prostate cancer (PCa) who are not eligible for radical treatment options. ADT is also used in patients with PCa as neo-adjuvant hormone therapy to reduce prostate volume and down-stage the disease before radiotherapy with curative intent. The present study showed that ADT with the gonadotropin hormone-releasing hormone (GhRH) antagonist degarelix is non-inferior to combined treatment with the LHRH agonist goserelin and bicalutamide in terms of reducing prostate volume during the treatment period of 3 months. Degarelix treatment evokes, however, significantly better relief of lower urinary tract symptoms in patients having moderate and severe voiding problems.
B J U International (print), 2012, Vol 110, Issue 11, p. 1721-8